| Identification | Back Directory | [Name]
ENTEROSTATIN, HUMAN | [CAS]
117830-79-2 | [Synonyms]
APGPR Enterostatin
ALA-PRO-ASP-PRO-ARG
ALA-PRO-GLY-PRO-ARG
ENTEROSTATIN, HUMAN
H-ALA-PRO-GLY-PRO-ARG-OH
Enterostatin , mouse, rat)
L-ALA-PRO-GLY-PRO-ARG SALT
H-ALA-PRO-GLY-PRO-ARG-OH ACOH
procolipase activation peptide
ENTEROSTATIN (HUMAN) ACETATE SALT
HUMAN PROCOLIPASE ACTIVATION PEPTIDE
H-ALA-PRO-GLY-PRO-ARG-OH ACETATE SALT
L-Arginine, L-alanyl-L-prolylglycyl-L-prolyl- | [Molecular Formula]
C21H36N8O6 | [MDL Number]
MFCD00133052 | [MOL File]
117830-79-2.mol | [Molecular Weight]
496.56 |
| Chemical Properties | Back Directory | [density ]
1.54±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
Soluble to 0.70 mg/ml in sterile water | [form ]
Lyophilized solid. | [pka]
3.60±0.21(Predicted) |
| Hazard Information | Back Directory | [Definition]
ChEBI: APGPR Enterostatin is a peptide. | [Biological Activity]
Enterostatin are pentapeptides that reduce fat intake. | [in vitro]
In the perfused ratpancreas, Enterostatin, at 100 mM, inhibits the insulin response to 9 mM glucose (by 70%), 0.1 mM tolbutamide (by 40%), and 5 mM arginine (by 70%). | [in vivo]
Chronically, enterostatin reduces fat intake, bodyweight, and body fat. This response may involve multiple metabolic effects of enterostatin, which include a reduction of insulin secretion, an increase in sympathetic drive to brown adipose tissue, and the stimulation of adrenal corticosteroid secretion. Enterostatin enhances memory consolidation after central or oral administration at a dose of 10 nmol/mouse or 300 mg/kg, respectively, in a step-through type passive avoidance test in mice. A dose of 38 nmol of enterostatin gives a significant inhibition of high-fat food intake, while at a higher dose of 76 nmol the inhibiting effect is lost. During the first hour, after injection of enterostatin, there is even a slight increase in food intake. | [target]
| Human Endogenous Metabolite < span> | |
|
|